The HIV drugs market is gaining momentum as rising infection rates and evolving drug resistance fuel the demand for advanced treatment options. Backed by public and private R&D investments, the market is forecasted to grow at a 6.21% CAGR through 2034, with Asia Pacific emerging as the fastest-growing region.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: HIV Drugs Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. HIV Drugs Market Revenue and Volume, By Medication Class
8.1.1 Multi-class Combination Drugs
8.1.1.1. Market Revenue and Volume Forecast
8.1.2. Nucleoside-Analog Reverse Transcriptase Inhibitors (NRTIs)
8.1.2.1. Market Revenue and Volume Forecast
8.1.3. Non-nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
8.1.3.1. Market Revenue and Volume Forecast
8.1.4. Entry & Fusion Inhibitors
8.1.4.1. Market Revenue and Volume Forecast
8.1.5. Protease Inhibitors (PIs)
8.1.5.1. Market Revenue and Volume Forecast
8.1.6. Integrase Inhibitors
8.1.6.1. Market Revenue and Volume Forecast
8.1.7. Coreceptor Antagonists
8.1.7.1. Market Revenue and Volume Forecast
9.1. HIV Drugs Market Revenue and Volume, By Drug Type
9.1.1. Branded Drugs
9.1.1.1. Market Revenue and Volume Forecast
9.1.2. Generic Drugs
9.1.2.1. Market Revenue and Volume Forecast
10.1. North America
10.1.1. Market Revenue and Volume Forecast, By Medication Class
10.1.2. Market Revenue and Volume Forecast, By Drug Type
10.1.3. U.S.
10.1.3.1. Market Revenue and Volume Forecast, By Medication Class
10.1.3.2. Market Revenue and Volume Forecast, By Drug Type
10.1.4. Rest of North America
10.1.4.1. Market Revenue and Volume Forecast, By Medication Class
10.1.4.2. Market Revenue and Volume Forecast, By Drug Type
10.2. Europe
10.2.1. Market Revenue and Volume Forecast, By Medication Class
10.2.2. Market Revenue and Volume Forecast, By Drug Type
10.2.3. UK
10.2.3.1. Market Revenue and Volume Forecast, By Medication Class
10.2.3.2. Market Revenue and Volume Forecast, By Drug Type
10.2.4. Germany
10.2.4.1. Market Revenue and Volume Forecast, By Medication Class
10.2.4.2. Market Revenue and Volume Forecast, By Drug Type
10.2.5. France
10.2.5.1. Market Revenue and Volume Forecast, By Medication Class
10.2.5.2. Market Revenue and Volume Forecast, By Drug Type
10.2.6. Rest of Europe
10.2.6.1. Market Revenue and Volume Forecast, By Medication Class
10.2.6.2. Market Revenue and Volume Forecast, By Drug Type
10.3. APAC
10.3.1. Market Revenue and Volume Forecast, By Medication Class
10.3.2. Market Revenue and Volume Forecast, By Drug Type
10.3.3. India
10.3.3.1. Market Revenue and Volume Forecast, By Medication Class
10.3.3.2. Market Revenue and Volume Forecast, By Drug Type
10.3.4. China
10.3.4.1. Market Revenue and Volume Forecast, By Medication Class
10.3.4.2. Market Revenue and Volume Forecast, By Drug Type
10.3.5. Japan
10.3.5.1. Market Revenue and Volume Forecast, By Medication Class
10.3.5.2. Market Revenue and Volume Forecast, By Drug Type
10.3.6. Rest of APAC
10.3.6.1. Market Revenue and Volume Forecast, By Medication Class
10.3.6.2. Market Revenue and Volume Forecast, By Drug Type
10.4. MEA
10.4.1. Market Revenue and Volume Forecast, By Medication Class
10.4.2. Market Revenue and Volume Forecast, By Drug Type
10.4.3. GCC
10.4.3.1. Market Revenue and Volume Forecast, By Medication Class
10.4.3.2. Market Revenue and Volume Forecast, By Drug Type
10.4.4. North Africa
10.4.4.1. Market Revenue and Volume Forecast, By Medication Class
10.4.4.2. Market Revenue and Volume Forecast, By Drug Type
10.4.5. South Africa
10.4.5.1. Market Revenue and Volume Forecast, By Medication Class
10.4.5.2. Market Revenue and Volume Forecast, By Drug Type
10.4.6. Rest of MEA
10.4.6.1. Market Revenue and Volume Forecast, By Medication Class
10.4.6.2. Market Revenue and Volume Forecast, By Drug Type
10.5. Latin America
10.5.1. Market Revenue and Volume Forecast, By Medication Class
10.5.2. Market Revenue and Volume Forecast, By Drug Type
10.5.3. Brazil
10.5.3.1. Market Revenue and Volume Forecast, By Medication Class
10.5.3.2. Market Revenue and Volume Forecast, By Drug Type
10.5.4. Rest of LATAM
10.5.4.1. Market Revenue and Volume Forecast, By Medication Class
10.5.4.2. Market Revenue and Volume Forecast, By Drug Type
11.1. AbbVie Inc.
11.1.1. Company Overview
11.1.2. Product Offerings
11.1.3. Financial Performance
11.1.4. Recent Initiatives
11.2. Boehringer Ingelheim International GmbH
11.2.1. Company Overview
11.2.2. Product Offerings
11.2.3. Financial Performance
11.2.4. Recent Initiatives
11.3. Bristol-Myers Squibb Company
11.3.1. Company Overview
11.3.2. Product Offerings
11.3.3. Financial Performance
11.3.4. Recent Initiatives
11.4. Cipla Inc.
11.4.1. Company Overview
11.4.2. Product Offerings
11.4.3. Financial Performance
11.4.4. Recent Initiatives
11.5. Genentech, Inc.
11.5.1. Company Overview
11.5.2. Product Offerings
11.5.3. Financial Performance
11.5.4. Recent Initiatives
11.6. Gilead Sciences, Inc.
11.6.1. Company Overview
11.6.2. Product Offerings
11.6.3. Financial Performance
11.6.4. Recent Initiatives
11.7. Merck & Co., Inc.
11.7.1. Company Overview
11.7.2. Product Offerings
11.7.3. Financial Performance
11.7.4. Recent Initiatives
11.8. ViiV Healthcare
11.8.1. Company Overview
11.8.2. Product Offerings
11.8.3. Financial Performance
11.8.4. Recent Initiatives
12.1. Primary Research
12.2. Secondary Research
12.3. Assumptions
13.1. About Us
13.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
Plan your call and get expert insights!
Schedule a Meeting
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Get a Sample
Report Description
Get a Sample
Report Description